HC Wainwright & Co. Maintains Buy on Purple Biotech, Lowers Price Target to $17
HC Wainwright & Co. analyst Emily Bodnar maintains Purple Biotech (NASDAQ:PPBT) with a Buy and lowers the price target from $30 to $17.
Read original at benzingaStocks · News reference
PPBT stock has given up its prior gain. Purple Biotech shares were trading higher after the company announced the presentation of new preclinical data from its lead CAPTN-3 program, IM1240, at EACR 2026 Annual Congress.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jun 11, 2026, 11:47 AM
- Checked
- Jun 11, 2026, 11:47 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
CORRECTION: Purple Biotech Q2 EPS $(0.41) Beats $(0.98) Estimate
Purple Biotech (NASDAQ:PPBT) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.98) by 58.16 percent. This is a 89.75 percent increase over losses of $(4.00) per share from
Read original at benzingaPurple Biotech Q2 EPS $(0.35) Beats $(0.98) Estimate
Purple Biotech (NASDAQ:PPBT) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.98) by 64.29 percent. This is a 91.25 percent increase over losses of $(4.00) per share from
Read original at benzinga